lonafarnib has been researched along with Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, IM | 1 |
| Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF | 1 |
| Castaneda, C; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Morse, MA; Petros, WP; Statkevich, P; Truax, R; Zhu, Y | 1 |
| Bender, L; Chanel-Vos, C; Escuin, D; Fanucchi, MP; Gal, A; Giannakakou, P; Harvey, RD; Kauh, J; Khuri, FR; Kutner, M; Marcus, A; Pan, L; Ramalingam, SS; Saba, N; Shin, DM | 1 |
| Adjei, AA; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Meyers, ML; Morse, MA; Petros, WP; Rosen, LS; Statkevich, P; Wong, NS; Zhu, Y | 1 |
| Morse, MA; Wong, NS | 1 |
| Adjei, AA; Dy, GK; Haluska, P | 1 |
| Awada, A; Bleiberg, H; Cutler, DL; Eskens, FA; Faber, MN; Fumoleau, P; Piccart, M; Statkevich, P; van der Gaast, A; Verweij, J; Wanders, J | 1 |
| Baum, CM; Kirschmeier, P; Taveras, AG | 1 |
| Bangert, S; Bishop, WR; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Kirschmeier, P; Lu, C; Meyers, ML; Munden, RF; Papadimitrakopoulou, V; Shin, DM; Statkevich, P; Tendler, C; Thall, PF; Thompson, E; Wang, XM; Zhu, Y | 1 |
| Helbig, G; HoĊowiecki, J | 1 |
| Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P | 1 |
| Basso, AD; Bishop, WR; Kirschmeier, P; Liu, G; Long, BJ; Mirza, A | 1 |
| Bukowski, RM; Curtis, D; Frank, E; Lipton, A; Ready, NE; Statkevich, P; Zhu, Y | 1 |
| Cutler, DL; Statkevich, P; Zhu, Y | 1 |
| Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S | 1 |
| Adjei, AA; Atherton, P; Bishop, WR; Cutler, DL; Davis, JN; Erlichman, C; Hanson, LJ; Kaufmann, SH; Kirschmeier, P; Marks, RS; Sloan, JA; Svingen, PA | 1 |
| Doll, RJ; Ganguly, AK; Girijavallabhan, VM | 1 |
| Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ | 1 |
9 review(s) available for lonafarnib and Neoplasms
| Article | Year |
|---|---|
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Design; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms | 2004 |
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones | 2013 |
Lonafarnib for cancer and progeria.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Progeria; Protein Prenylation; Pyridines; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Farnesyl transferase inhibitors as anticancer agents.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured | 2002 |
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Molecular Structure; Neoplasms; Piperidines; Protein Conformation; Pyridines | 2003 |
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction | 2004 |
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins | 2005 |
Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Molecular Structure; Neoplasms; Piperidines; Protein Conformation; Pyridines | 2001 |
Current status of clinical trials of farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction | 2001 |
8 trial(s) available for lonafarnib and Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Area Under Curve; Enzyme Inhibitors; Female; Humans; Lamin Type A; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Nuclear Proteins; Piperidines; Protein Precursors; Pyridines; Treatment Outcome | 2011 |
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Piperidines; Pyridines; Taxoids | 2011 |
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2011 |
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Pyridines | 2002 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperidines; Pyridines; Treatment Outcome | 2004 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Piperidines; Pyridines; Time Factors | 2007 |
Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
Topics: Adult; Aged; Analysis of Variance; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2007 |
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lamin Type A; Lamins; Male; Middle Aged; Mouth Mucosa; Neoplasms; Nuclear Proteins; Piperidines; Protein Precursors; Pyridines | 2000 |
2 other study(ies) available for lonafarnib and Neoplasms
| Article | Year |
|---|---|
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Caspases; Cell Line, Tumor; Farnesyltranstransferase; Humans; Monomeric GTP-Binding Proteins; Neoplasms; Neuropeptides; Phosphorylation; Piperidines; Protein Kinases; Protein Prenylation; Pyridines; Ras Homolog Enriched in Brain Protein; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Tamoxifen; Taxoids; TOR Serine-Threonine Kinases | 2005 |
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |